Clinical Trial Update: Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety and efficacy of sunitinib malate as first-line therapy in Chinese patients with metastatic renal cell carcinoma; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Phase 4 | Status: COMPLETED | Results posted: 2012-12-20